Rapid identification of chemical/drug toxicity, toxicological profiles and modes of action, mechanistic toxicity studies and investigation of adverse outcome pathways, via real-time monitoring of multiple toxicity endpoints in living C. elegans worms.
In vivo high-content screening of drugs and active compounds on transgenic/mutant C. elegans strains of interest – e.g. C. elegans models for human diseases – as a novel time- and cost-effective way to boost drug discovery and lead optimization.
Contact our scientists to discuss your project requirements and timeline.
Send us the samples to be tested/used in your project.
Your project will be executed by our scientists using Nagi’s unique Organism-on-Chip technology.
A detailed report about your project results will be prepared, sent to you and discussed with you.